All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @journeyto150marthaf on TikTok · 50s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @journeyto150marthaf's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00You're not sick. No, no, in fact
  2. 0:03When I'm hungry and I wish I had a snack
  3. 0:08So that's what keeps happening
  4. 0:10It's like I'll take a few bites
  5. 0:12And I legit feel like I want to throw up
  6. 0:16This is barely maybe let's say three hours in and I swear to you
  7. 0:21It's the after I
  8. 0:25Just had a little piece of granola bar
  9. 0:27Here because I'm here at Costco and I legit wanted to throw up I
  10. 0:33Am three hours in so
  11. 0:35This is
  12. 0:38interesting
  13. 0:41You like the smells I just try to eat that chicken
  14. 0:45Nope, I can't oh man. This is insane

TikTok star's semaglutide nausea experience, fact-checked

Journey to 150 | Martha F ♥️

TikTok creator

863.8K viewsWatch on TikTok

Quick answer

The creator experienced nausea approximately three hours post-dose when attempting to eat a granola bar and then chicken, consistent with the GI side effect profile of semaglutide during early treatment or dose escalation. Nausea affects roughly 44% of patients on semaglutide 2.4mg per the STEP 1 trial and typically peaks during the titration phase. The creator's interpretation that nausea confirms efficacy is not supported by the pharmacological mechanism; nausea is a byproduct of delayed gastric emptying, not the weight loss pathway itself.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For TikTok star's semaglutide nausea experience, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "TikTok star's semaglutide nausea experience, fact-checked" from Journey to 150 | Martha F ♥️. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator experienced nausea approximately three hours post-dose when attempting to eat a granola bar and then chicken, consistent with the GI side effect profile of semaglutide during early treatment or dose escalation.

The reason this review is not generic is the source wording and the canonical claim label "glp1 am i the only one who felt this nauseous so soon with sem." In this clip, the useful excerpt is: "You're not sick." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Nausea is a side effect of slowed gastric emptying, not a direct signal that weight loss is happening.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator experienced nausea approximately three hours post-dose when attempting to eat a granola bar and then chicken, consistent with the GI side effect profile of semaglutide during early treatment or dose escalation.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator experienced nausea approximately three hours post-dose when attempting to eat a granola bar and then chicken, consistent with the GI side effect profile of semaglutide during early treatment or dose escalation. Nausea affects roughly 44% of patients on semaglutide 2.4mg per the STEP 1 trial and typically peaks during the titration phase. The creator's interpretation that nausea confirms efficacy is not supported by the pharmacological mechanism; nausea is a byproduct of delayed gastric emptying, not the weight loss pathway itself.
  • 44% of patients on semaglutide 2.4mg reported nausea in the STEP 1 trial (Wilding et al., 2021, NEJM), so this is common and expected, not a unique or alarming experience.
  • Nausea is a side effect of slowed gastric emptying, not a direct signal that weight loss is happening. Patients who experience it do not reliably lose more weight than those who don't.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • 44% of patients on semaglutide 2.4mg reported nausea in the STEP 1 trial (Wilding et al., 2021, NEJM), so this is common and expected, not a unique or alarming experience.
  • Nausea is a side effect of slowed gastric emptying, not a direct signal that weight loss is happening. Patients who experience it do not reliably lose more weight than those who don't.
  • Severe or persistent nausea should be reported to a prescriber. The FDA Wegovy label specifically flags this as a reason to seek medical guidance, not push through it.
  • Eating smaller, lower-fat meals and staying upright after eating are first-line recommendations for managing GLP-1-related nausea per Obesity Medicine Association guidelines.
  • Compounded semaglutide is not equivalent to FDA-approved Wegovy or Ozempic and is not subject to the same manufacturing standards. Dosing and side effect profiles may differ.
  • Per Butsch et al. (2023, Obesity Reviews), nausea severe enough to dramatically restrict food intake can increase the risk of losing lean muscle mass rather than fat, which is a counterproductive outcome.
  • Social media normalization of GLP-1 side effects, while relatable, can discourage patients from reporting symptoms that warrant clinical attention or dose adjustment.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @journeyto150marthaf actually say?

She described feeling like she wanted to throw up roughly three hours after taking semaglutide, triggered by eating a small piece of granola bar and then trying chicken at Costco. Her conclusion: "This is working for sure." That framing, nausea as proof of efficacy, is the claim worth examining here.

To be fair, she wasn't making a formal medical claim. She was documenting a real experience in real time, which is exactly the kind of content that gets 860K views because it feels relatable. But that same relatability is why the interpretation matters. Millions of people are starting GLP-1 medications and watching these videos to understand what to expect. "It's working" is not the same as "this is expected" or "this is safe."

Does the science back this up?

Nausea is genuinely one of the most common side effects of semaglutide. It's not a myth. But nausea being "proof it's working" is a significant oversimplification that the clinical data does not support.

In the STEP 1 trial (Wilding et al., 2021, NEJM), nausea was reported by 44% of participants on semaglutide 2.4mg versus 16% on placebo. It was most common during dose escalation and typically peaked in the first few weeks. Importantly, participants who experienced nausea did not show meaningfully greater weight loss than those who did not. The weight loss mechanism in semaglutide works primarily through GLP-1 receptor agonism in the hypothalamus and gut, slowing gastric emptying and reducing appetite. Nausea is a side effect of that slowing, not the mechanism of weight loss itself.

A 2023 review by Butsch et al. in Obesity Reviews noted that nausea often diminishes over time without dose adjustment, and that persistent nausea severe enough to limit food intake can actually increase the risk of lean muscle loss rather than fat loss, which is the opposite of a desired outcome.

What did they get wrong (or right)?

She got the basic experience right. Early nausea with semaglutide is real and common. The smell sensitivity she described, "you like the smells," aligns with documented GI hypersensitivity during early GLP-1 treatment. These are not fabricated symptoms.

What she got wrong is the interpretation. Framing nausea as confirmation that the drug is "working" conflates a side effect with a therapeutic effect. This is a meaningful distinction. If a patient believes nausea equals efficacy, they may be reluctant to report it to their provider, avoid dose adjustments, or push through symptoms that warrant medical attention.

Severe or persistent nausea can indicate gastroparesis risk, especially at higher doses. The FDA label for Wegovy specifically instructs patients to contact their provider if nausea is severe or does not go away. Three hours post-dose nausea triggered by a granola bar and chicken is worth mentioning to a prescriber, not celebrating as a sign of success.

  • Correct: nausea is a common early side effect
  • Correct: food smells and certain textures can be triggering
  • Misleading: nausea as confirmation of drug efficacy
  • Missing: any guidance to consult a provider about the symptom

What should you actually know?

Nausea on semaglutide is expected but not desirable, and it is not a marker that your dose is optimal or your weight loss will be greater. The drug works whether or not you feel sick.

If you are experiencing nausea this early and this intensely, the standard clinical guidance, per the Wegovy prescribing information and the Obesity Medicine Association, is to eat smaller meals, avoid high-fat or high-sugar foods, eat slowly, and stay upright after eating. If nausea is severe enough to stop you from eating almost anything, that conversation belongs with your prescriber, not just a TikTok comment section.

There is also a compounding note worth making here. A significant portion of people starting semaglutide right now are using compounded versions, not FDA-approved Wegovy or Ozempic. Compounded semaglutide is not equivalent to the brand-name drug in terms of regulatory oversight, and dosing protocols can vary significantly. If your nausea is extreme, your dose source matters to your provider.

The broader takeaway is that GLP-1 side effect content on social media tends to normalize symptoms without contextualizing them. That normalization can delay people from reporting problems that actually need attention.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Journey to 150 | Martha F ♥️ · TikTok creator

863.8K views on this video

🤢 Am I the only one who felt this nauseous so soon with Semaglutide??? This is crazy!! Semaglutide is working for sure!! #healthweightloss #semaglutide #weightlossjouney #weightloss #foryou #newme #w

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about 44% of patients on semaglutide 2.4mg reported nausea in the?

44% of patients on semaglutide 2.4mg reported nausea in the STEP 1 trial (Wilding et al., 2021, NEJM), so this is common and expected, not a unique or alarming experience.

What does the video say about nausea?

Nausea is a side effect of slowed gastric emptying, not a direct signal that weight loss is happening. Patients who experience it do not reliably lose more weight than those who don't.

What does the video say about severe?

Severe or persistent nausea should be reported to a prescriber. The FDA Wegovy label specifically flags this as a reason to seek medical guidance, not push through it.

What does the video say about eating smaller, lower-fat meals?

Eating smaller, lower-fat meals and staying upright after eating are first-line recommendations for managing GLP-1-related nausea per Obesity Medicine Association guidelines.

What does the video say about compounded semaglutide?

Compounded semaglutide is not equivalent to FDA-approved Wegovy or Ozempic and is not subject to the same manufacturing standards. Dosing and side effect profiles may differ.

What does the video say about per butsch et al. (2023, obesity reviews), nausea severe enough?

Per Butsch et al. (2023, Obesity Reviews), nausea severe enough to dramatically restrict food intake can increase the risk of losing lean muscle mass rather than fat, which is a counterproductive outcome.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Journey to 150 | Martha F ♥️, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.